Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New home program aims to boost memory and ease daily life for MS patients

NCT ID NCT06951919

Symptom relief Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a home-based program called HOBSCOTCH-MS for people with multiple sclerosis who have memory or thinking problems. Participants meet virtually with a coach for 8 weekly sessions to learn problem-solving and relaxation skills. The goal is to improve quality of life and cognitive function for MS patients and reduce burden for their caregivers. The study involves 125 participants and lasts about 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inclusion Criteria - MS Participant * Age 20 - 75 years * Diagnosis of relapsing or progressive MS * Education of at least Grade 12 or GED * Fluent in English * Subjective cognitive and memory challenges * Internet access * Telephone access Inclusion Criteria - Caregiver Participant * 20 years + * Fluent in English * Caregiver to a MS Participant * Participant MS has given permission to Caregiver to enroll with them * Internet access * Telephone access Exclusion Criteria: * Exclusion Criteria MS Participant * Current diagnosed psychiatric disorders (e.g., schizophrenia, bipolar disorder or substance use disorder). * Other neurological disorder such as epilepsy, brain tumor, severe brain injury or mild to moderate brain injury with a history of 30 or more minutes' loss of consciousness, or other disorder that would confound the focus on MS * Diagnosed developmental attention, learning, or intellectual disorder; sensory, motor, or physical disability that would prevent engagement with the intervention or render the person unable complete study outcome measures * Exacerbation of MS symptoms (relapse) or ongoing steroid treatment within three months of study enrollment * Significant visual impairment precluding reading or writing * Lack of access to the technical resources (e.g., internet access, telephone) required for participation Exclusion Criteria - Caregiver Participant * Significant visual impairment precluding reading or writing * No reliable telephone or internet access

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Caregiver Burden cognitive disorder Cognitive Dysfunction Memory Disorders multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive dysfunction Memory disorders Memory dysfunction Memory impairment Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dartmouth-Health Lebanon

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.